Skip to main content
ALEMBIC PHARMACEUTICALS LIMITED logo

ALEMBIC PHARMACEUTICALS LIMITED — Investor Relations & Filings

Ticker · APLLTD ISIN · INE901L01018 LEI · 335800PM173KNG818V30 BSE.NS Manufacturing
Open in API
Filings indexed 1,367 across all filing types
Latest filing 2026-04-08 Regulatory Filings
Country IN India
Listing BSE.NS APLLTD

About ALEMBIC PHARMACEUTICALS LIMITED

https://www.alembicpharmaceuticals.com

Alembic Pharmaceuticals Limited is a vertically integrated pharmaceutical organization engaged in the development, manufacturing, and marketing of generic pharmaceutical products, active pharmaceutical ingredients (APIs), and formulations. Established in 1907, the company operates advanced research and development centers and manufacturing facilities that adhere to international regulatory standards, including USFDA compliance. Its diverse product portfolio covers key therapeutic areas such as anti-infectives, cardiology, gynecology, gastrointestinal, and dermatology. Alembic maintains a strong global presence, supplying high-quality medications to markets in North America, Europe, and various emerging regions. The company prioritizes innovation through its focus on complex generics and specialty products, aiming to provide affordable and effective healthcare solutions worldwide.

Recent filings

Filing Released Lang Actions
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings
2026-04-08 English
Press Release
Regulatory Filings Classification · 95% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) about Alembic Pharmaceuticals Limited receiving USFDA final approval for a drug product. It includes a press release detailing the approval, market size, and company background. The document is short (4097 characters) and primarily serves as an announcement of a significant corporate event (regulatory approval) rather than a financial report or detailed filing. There is no financial data, no mention of earnings, no management discussion, no voting results, or other regulatory filings typical of financial reports. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under a general regulatory announcement category informing the market about a material event. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2026-04-07 English
Appointment
Board/Management Information Classification · 100% confidence The document is an official communication addressed to stock exchanges regarding the appointment of Mr. Chirayu Amin as Executive Chairman and his relinquishment of the CEO position. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30, which pertains to disclosures about changes in the company's board or senior management. The content includes detailed information about the appointment, term, and profile of the director, which aligns with announcements of changes in board or management. There is no financial data or report attached, nor is it a report publication announcement. Therefore, this document fits the category of Board/Management Information (MANG).
2026-04-01 English
Cessation
Board/Management Information Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the appointment of Mr. Chirayu Amin as Executive Chairman and his relinquishment of the CEO position. It includes details about the appointment, term, and profile of the director. There is no financial data or report content, but rather a corporate governance update about board management changes. This fits the category of Board/Management Information (MANG). The document length is 4706 characters, which is sufficient for a detailed announcement but not a full report. Therefore, the classification is MANG with high confidence.
2026-04-01 English
Appointment
Board/Management Information Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the re-appointment of Mr. Pranav Amin as Managing Director of the company. It references the shareholders' approval at the 15th Annual General Meeting and provides details about the appointment and related disclosures. The document is addressed to stock exchanges and serves as an official announcement of a change in senior management. It does not contain financial statements or detailed financial analysis but focuses on management appointment information. Therefore, it fits the category of Board/Management Information (MANG). The document length is 3646 characters, which is consistent with an announcement rather than a full report.
2026-04-01 English
Appointment
Board/Management Information Classification · 100% confidence The document is an official intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the appointment of Mr. Rajkumar Baheti as a Non-Executive Non-Independent Director of Alembic Pharmaceuticals Limited, effective from 1st April 2026. The document includes details about the appointment, the reason for change, and the director's profile. There is no financial data, earnings information, or report attached. The content clearly relates to a change in the company's board of directors. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 3595 characters, which is consistent with a detailed announcement rather than a full report or a brief notice. Confidence in classification is high due to explicit mention of director appointment and regulatory references specific to board changes.
2026-04-01 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.